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Background: Acute respiratory failure (ARF) and severe sepsis (SS) are possible complications in patients with
community-acquired pneumonia (CAP). The aim of the study was to evaluate prevalence, characteristics, risk factors
and impact on mortality of hospitalized patients with CAP according to the presence of ARF and SS on admission.
Methods: This was a multicenter, observational, prospective study of consecutive CAP patients admitted to three
hospitals in Italy, Spain, and Scotland between 2008 and 2010. Three groups of patients were identified: those with
neither ARF nor SS (Group A), those with only ARF (Group B) and those with both ARF and SS (Group C) on
admission.
Results: Among the 2,145 patients enrolled, 45% belonged to Group A, 36% to Group B and 20% to Group C.
Patients in Group C were more severe than patients in Group B. Isolated ARF was correlated with age (p < 0.001),
COPD (p < 0.001) and multilobar infiltrates (p < 0.001). The contemporary occurrence of ARF and SS was associated
with age (p = 0.002), residency in nursing home (p = 0.007), COPD (p < 0.001), multilobar involvement (p < 0.001)
and renal disease (p < 0.001). 4.2% of patients in Group A died, 9.3% in Group B and 26% in Group C, p < 0.001.
After adjustment, the presence of only ARF had an OR for in-hospital mortality of 1.85 (p = 0.011) and the presence
of both ARF and SS had an OR of 6.32 (p < 0.001).
Conclusions: The identification of ARF and SS on hospital admission can help physicians in classifying CAP patients
into three different clinical phenotypes.
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Community-acquired pneumonia (CAP) is widely recog-
nized as a major cause of morbidity and mortality [1].
Clinically, CAP exhibits an extreme variety in the sever-
ity of presentation, from almost asymptomatic disease at
one side to a fulminant event to the other [2,3].
From a pathophysiological point of view, pneumonia
can be complicated by the occurrence and interaction of
two processes. On one hand, alveolar inflammation may* Correspondence: francesco.blasi@unimi.it
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unless otherwise stated.result in serious ventilation-perfusion mismatch with the
development of acute respiratory failure (ARF) that is
shown to be associated, even in patients with mild pneu-
monia, with worse clinical outcomes [4]. On the other
hand, decompartmentalization of the infection along
with uncontrolled systemic inflammatory response might
lead to the development of severe sepsis (SS). These two
processes are linked together since interaction between
hypoxia and inflammation has been proven at both mo-
lecular and cellular levels [5].
The natural history of pneumonia could be seen as a
continuum from a local disease with neither respiratory
nor multi-organ failure to a local disease leading to iso-
lated respiratory failure to a systemic disease involvingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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true, we would expect to see different clinical outcomes
according to this three-stage model.
In order to test this hypothesis, we decided to evaluate
prevalence, characteristics, risk factors, and impact on
clinical outcomes of CAP patients with neither ARF nor
SS, those with only ARF, and those with both ARF and
SS on hospital admission.
Methods
Study design and setting
This was a multicenter, observational, prospective study
of consecutive patients coming from the community who
were admitted to the Policlinico Hospital (Milan, Italy),
Hospital Clinìc (Barcelona, Spain) and NHS Hospitals
(Edinburgh, UK) with diagnosis of pneumonia between
April 2008 and April 2010. The Institutional Review Boards
of all the hospitals approved the study. Patients >18 years
of age who satisfied the criteria for pneumonia were in-
cluded in the study. The following subjects were excluded:
a) patients who were hospitalized in the previous 15 days;
b) patients with a diagnosis of active tuberculosis or infec-
tion with fungi; c) immunosuppressed patients as those
with HIV infection, neutropenia, on immunosuppressive
therapy, chemotherapy, transplantation, cytotoxic therapy,
and chronic systemic steroid therapy.
The following data were recorded: demographics; past
medical history; severity of symptoms on admission; pneu-
monia severity index (PSI) and CURB-65 score; physical,
laboratory, and radiological findings on admission; micro-
biological data; empiric antibiotic therapy; in-hospital
mortality [6,7]. Blood gas analysis on admission was per-
formed based on local standard operating procedures.
Study definitions
Pneumonia was defined as the presence of a new pul-
monary infiltrate on chest radiograph at the time of
hospitalization associated with one or more of the fol-
lowing: (1) new or increased cough with/without sputum
production; (2) fever (>= 37.8°C) or hypothermia (< 35.6°C);
or (3) abnormal white blood cell count (either leukocytosis
or leukopenia), or C-reactive protein values above the local
upper limit.
Acute respiratory failure was defined as the presence of at
least one among the following on admission: 1) partial pres-
sure of oxygen in arterial blood (PaO2) < 60 mmHg; 2) ratio
of PaO2 and fraction of inspired oxygen (PaO2/FiO2) < 300;
3) oxygen saturation < 90%; 4) respiratory acidosis, and
5) ventilatory support. Respiratory acidosis was consid-
ered when a pH value on admission of less than 7.35
was identified with a partial pressure of carbon dioxide
in arterial blood (PaCO2) ≥ 45 mmHg.
Severe sepsis was defined as the presence of at least one
of the following signs of organ hypoperfusion or organdysfunction on admission: 1) sepsis-induced hypotension;
2) lactate greater than 2 mmol/L; 3) urine output <0.5 mL/
kg hr for >2 hours; 4) creatinine >2.0 mg/dL; 5) biliru-
bin >2 mg/dL; platelet count <100,000 cell/L−1; 6) coagu-
lopathy (international normalized ratio >1.5), as previously
reported [8].
Microbiology and empiric antibiotic therapy
Microbiological examinations were performed on spu-
tum, urine, and blood during the first 24 hours after
admission and according to standards of practice [9].
Empiric antibiotic therapy was administered as soon as
the diagnosis of pneumonia was reached in the emer-
gency department. The empiric antibiotic treatment was
evaluated for compliance with the European Respiratory
Society guidelines [10].
Study groups and outcomes
Among the entire study population three groups of pa-
tients were identified based on the presence of ARF and
SS on hospital admission: those with neither ARF nor SS
(Group A), those with only ARF (Group B), and those
with both ARF and SS (Group C) on hospital admission.
Each single case of patients with a PaO2/FiO2 ratio be-
tween 300 and 315 and those with a creatinine more
than 2 mg/dL on admission in the presence of chronic
renal failure who could not be categorized into either
group (n = 105) were reviewed by a clinical committee
composed of two pulmonary (SA and FB) and one infec-
tious disease physician (JR). After a comprehensive
evaluation of all the available information, the commit-
tee was able to assign all the patients to one of the three
study groups. In-hospital mortality and length of stay in
the hospital (LOS) were the study outcomes. LOS was
calculated as the number of days from the date of ad-
mission to the date of discharge.
Statistical analysis
All data were statistically analyzed using SPSS (version
18.0) for Mac. Descriptive statistics were reported at base-
line, with continuous data expressed as a median (25–75
interquartile range -IQR) and categorical data expressed
as counts. Patient characteristics were compared between
groups. Differences of continuous data between two
groups were evaluated by Mann–Whitney U test (two
groups) or Kruskal-Wallis test (three groups). Differences
of categorical variables between two or more groups were
analyzed using the X2 test or Fisher exact test where ap-
propriate. The center effect on mortality was tested using
a meta-analytical approach run in R [11,12]. Potential pre-
dictors of an adverse event that were considered of clinical
relevance and immediately accessible on admission were
investigated with the multivariable binomial logistic re-
gression analysis and included: sex, age, comorbidities
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COPD, liver disease), nursing home residency, multilobar
infiltrate and pleural effusion. The cumulative probability
of survival over 14 days was tested with a Kaplan-Mayer
analysis. In order to detect the pneumonia-related mortal-
ity, patients who died after 14 days from admission were
considered to be alive for the purpose of the Kaplan-
Mayer analysis. The reliability of the obtained results was
also tested adjusting the survival analysis by center and
confounders that were considered of clinical relevance
and immediately accessible on admission using the Cox
analysis. A p value <0.05 was considered statistically sig-
nificant and was adjusted for multiplicity according to the
Bonferroni criterion.
Results
Prevalence, characteristics, and risk factors for ARF and SS
A total of 2,145 consecutive patients with pneumonia
were enrolled during the study period: 47% were males
and median (IQR) age was 73 (56–82) years. Data to de-
fine either ARF or SS on admission were not available in
367 patients. A sensitivity analysis was performed check-
ing whether the main outcome was different between
the three circumstances: excluding patients with infor-
mation not recorded; attributing missing information to
non-ARF and/or non-SS; attributing missing information
to ARF and/or SS. The three analyses yielded superim-
posed results (confidence intervals completely overlap-
ping). Consequently, it was assumed that non-recorded
data were in the normal range, and these patients were
classified as non-ARF and/or non-SS.
Among the entire study population, 954 (45%) patients
had neither ARF nor SS on admission (Group A). The
presence of ARF alone was identified in 771 (36%) pa-
tients (Group B) and of both ARF and SS on admission
in 420 (20%) patients (Group C). No patients with SS and
without ARF were identified. Among patients with SS, the
frequencies of organ failure were as follows: sepsis-
induced hypotension in 204 (49%), creatinine >2.0 mg/dL
in 140 (33%), urine output <0.5 mL/kg hr for >2 hours in
84 (20%), lactate greater than 2 mmol/L in 69 (16%), plate-
let count <100,000 cell/L−1 in 45 (11%), bilirubin >2 mg/dL
in 36 (8.6%) and coagulopathy in 26 (6.2%) patients.
Demographics, severity of disease, clinical, laboratory, and
radiological findings on admission, microbiology and em-
piric antibiotic therapy of the three study groups are sum-
marized in Table 1. In comparison to patients with ARF
alone, those with both ARF and SS on admission had
more comorbidities, a more diffuse radiological involve-
ment (p = 0.003), were more hypoxemic (p < 0.001) and
with a higher proportion of patients on respiratory acid-
osis (p = 0.014).
Centers, demographics, comorbidities, and radiological
findings were tested in multivariate logistic regression aspotential predictors of outcome, and age (p < 0.001), the
presence of COPD (p < 0.001), and multilobar infiltrates
on CXR (p < 0.001) resulted significantly associated with
isolated ARF on admission. Centers, demographics, co-
morbidities, and radiological findings were tested in
multivariate logistic regression as potential predictors of
outcome, and age (p = 0.002), residency in nursing home
(p = 0.007), the presence of COPD (p < 0.001), multilobar
involvement (p < 0.001), and renal disease (p < 0.001) re-
sulted significantly associated with the contemporary oc-
currence of ARF and severe sepsis on admission, see
Table 2.
The impact of ARF and SS on mortality
A total of 223 patients (10%; 95% CI: 9.2%-11.8%) among
the study population died during hospitalization. The
meta-analysis of the absolute risk difference in mortality
between the study groups failed to exhibit a significant
heterogeneity by centers, see Additional file 1: Table S1
and Additional file 2: Figure S1. The in-hospital mortal-
ity of the study population is summarized in Figure 1 ac-
cording to the three study groups. A total of 43 patients
died in Group A (4.2%; 95% CI: 3.3%-6.1%), 72 patients
in Group B (9.3%; 95% CI: 7.4%-11.7%), and 108 patients
in Group C (26%; 95% CI: 22%-30%), p < 0.001. The sur-
vival analysis showed a significant difference in terms of
time to death among the three study groups: 13.6 days
(Group A) vs. 13.2 days (Group B), p = 0.005; 13.6 days
(Group A) vs. 11.9 days (Group C), p < 0.001 (Log Rank
test). The Cox survival analysis confirmed these results
after adjusting for several confounders, see Figure 2.
Factors associated with in-hospital mortality in the
study population at the univariate analysis are shown in
Additional file 1: Table S1. At the multivariable logistic
regression model (1,891 patients; Nagelkerke R2: 0.253;
p from the Hosmer-Lemeshow test = 0.105), after adjust-
ment for centers and several confounders, the presence of
only ARF on admission had an OR for in-hospital mortal-
ity of 1.85 (95% CI: 1.15-2.98, p = 0.011) and the presence
of both ARF and SS on admission had an OR of 6.32 (95%
CI: 3.97-10, p < 0.001), see Figure 3. The presence of mul-
tilobar infiltrate on CXR showed an adjusted OR for mor-
tality of 2.09 (95% CI: 1.43-3.04, p < 0.001).
Figure 4 summarizes the mortality in patients with iso-
lated ARF on admission, according to PaO2/FiO2 ratio
and the presence of multilobar infiltrate on CXR. No
significant difference in mortality was detected in these
patients (Group B) according to the presence of monolo-
bar vs. multilobar involvement on CXR (38/479 patients,
7.9% vs. 19/180 patients, 11%, p = 0.350). No significant
difference in mortality was observed in Group B among
patients with different levels of PaO2/FiO2 ratio, regard-
less of multilobar involvement. Mortality in patients with
both ARF and SS on admission is depicted in Figure 4,
Table 1 Demographics, severity of disease, clinical, laboratory, radiological findings on admission, microbiology and
empiric antibiotic therapy of the study population, according to the three study groups




n. (%) 954 (100) 771 (100) 420 (100)
Demographics
Male, n. (%) 451 (47) 368 (48) 186 (44) 0.492 0.255
Age, median (IQR) years 67 (47–81) 75 (61–83) 75 (61–84) <0.001 0.868
Comorbidities, n. (%)
Congestive heart failure 148 (16) 170 (22) 103 (25) <0.001 0.332
Chronic obstructive pulmonary
disease
139 (15) 237 (31) 115 (27) <0.001 0.225
Diabetes mellitus 111 (12) 118 (15) 61 (15) 0.069 0.731
Cerebrovascular disease 83 (9) 93 (12) 70 (17) <0.001 0.027
Chronic renal failure 63 (7) 63 (8) 68 (16) <0.001 <0.001
Liver disease 52 (6) 27 (4) 32 (8) 0.008 0.002
Residency in a nursing home 46 (5) 63 (8) 54 (13) <0.001 0.009
Severity on admission, n. (%)
PSI Risk Class IV and V 332 (35) 464 (60) 343 (82) <0.001 <0.001
CURB-65 score 3, 4 and 5 127 (13) 198 (26) 231 (55) <0.001 <0.001
Admission to ICU 6 (0.6) 54 (7) 90 (21) <0.001 <0.001
Physical findings on admission,
median (IQR)
Systolic blood pressure, mmHg 127 (112–145) 130 (115–150) 108 (85–133) <0.001 <0.001
Diastolic blood pressure, mmHg 70 (64–80) 71 (62–80) 60 (50–72) <0.001 <0.001
Heart rate, beats/minute 95 (83–107) 100 (85–114) 110 (100–120) <0.001 <0.001
Respiratory rate, breaths/minute 20 (18–26) 24 (20–30) 30 (24–34) <0.001 <0.001
SpO2,% 96 (95–97) 92 (89–95) 90 (85–93) <0.001 <0.001
Laboratory values, median (IQR)
Arterial pH 7.45 (7.42-7.48) 7.44 (7.40-7.48) 7.39 (7.31-7.46) <0.001 <0.001
PaO2/FiO2 ratio 339 (318–378) 256 (216–279) 229 (182–276) <0.001 <0.001
PaCO2, mmHg 33 (29–38) 36 (31–42) 36 (30–48) <0.001 0.164
Respiratory acidosis, n. (%) 0 (0) 59 (8) 47 (13) <0.001 0.014
White blood cells, cell/L−1 11900 (8238–16300) 12790 (9100–17000) 144000 (9993–19000) <0.001 0.001
Platelet, cell/L−1 232000 (182000–300500) 237000 (186500–317000) 233000 (166750–307250) 0.054 0.028
Hemoglobin, g/dL 13 (12–14) 13 (12–14) 13 (11–14) 0.010 0.021
Hematocrit,% 39 (36–42) 40 (37–44) 39 (34–43) <0.001 0.001
Urea, mg/dL 37 (27–54) 45 (31–64) 63 (42–103) <0.001 <0.001
Creatinine, mg/dL 0.9 (0.8-1.2) 1.0 (0.8-1.2) 1.2 (0.9-1.9) <0.001 <0.001
Sodium, mEq/L 137 (134–139) 137 (134–139) 136 (133–140) 0.650 0.409
Glucose, mg/dL 105 (73–128) 113 (74–148) 101 (65–149) 0.002 0.035
Radiology findings on CXR, n. (%)
Multilobar involvement 161 (18) 195 (28) 141 (36) <0.001 0.003
Pleural effusion 204 (22) 150 (20) 100 (24) 0.209 0.078
Microbiological findings, n. (%)
Patients with isolated bacteria 184 (19) 198 (26) 141 (34) <0.001 0.004
Polymicrobial infection 3 (2) 8 (4) 4 (3) 0.369 0.547
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Table 1 Demographics, severity of disease, clinical, laboratory, radiological findings on admission, microbiology and
empiric antibiotic therapy of the study population, according to the three study groups (Continued)
Patients with > = one MDR
pathogen
17 (4) 20 (5) 22 (8) 0.015 0.060
S. pneumoniae 90 (49) 114 (58) 64 (45) 0.064 0.027
S. aureus 15 (8) 19 (10) 23 (16) 0.049 0.064
Legionella pneumophila 16 (9) 16 (8) 5 (4) 0.156 0.088
Respiratory viruses 11 (6) 12 (6) 13 (9) 0.439 0.273
Atypicals 31 (17) 22 (11) 9 (6) 0.014 0.137
H. influenzae 17 (9) 14 (7) 7 (5) 0.328 0.419
Empiric antibiotic therapy, n. (%)
Levofloxacin 287 (30) 234 (30) 106 (25) 0.133
Ceftriaxone 348 (37) 324 (42) 145 (35) 0.015
Amoxicillin (clavulanate) 295 (31) 218 (28) 148 (35) 0.045
Azithromycin 230 (24) 189 (25) 72 (17) 0.007
Clarithromycin 198 (21) 211 (27) 152 (36) <0.001
Piperacillin/tazobactam 34 (3.6) 44 (5.7) 43 (10) <0.001
Antibiotics compliant with
local guidelines
731 (81) 595 (79) 328 (79) 0.606 0.933
Outcomes
Length of hospital stay,
median (IQR) days
6 (3–11) 9 (6–14) 12 (7–21) <0.001 0.004
In-hospital mortality, n. (%) 43 (4.2) 72 (9.3) 108 (26) <0.001 <0.001
n: number; IQR: 25–75 interquartile range; COPD: chronic obstructive pulmonary disease; CAP: community-acquired pneumonia; PSI: pneumonia severity index;
ICU: intensive care unit; CXR: chest radiograph; ESBL: extended-spectrum beta-lactamase; MDR: multidrug resistant (including methicillin-resistant S. aureus,
Pseudomonas aeruginosa resistant to antipseudomonal penicillins, cephalosporins, carbapenems, and quinolones, Stenotrophomonas maltophilia, vancomycin-resistant
Enterococcus, Acinetobacter baumanii, extended spectrum b-lactamase producing Enterobacteriaceae, and other non-fermenting Gram-negative bacilli); SpO2: oxygen
saturation; PaO2: partial pressure of oxygen in arterial blood; PaCO2: partial pressure of carbon dioxide in arterial blood.
+Hypotension defined as Systolic blood
pressure <90 mm Hg or diastolic blood pressure < 60 mm Hg. Differences in continuous variables were monitored with Kruskal-Wallis test (three groups) and
Mann–Whitney U Test differences (two groups); differences in proportions were monitored with ANOVA (three groups) and the chi square test (two groups).
Group A: Community-acquired pneumonia (CAP) patients with neither acute respiratory failure (ARF) nor severe sepsis (SS) on admission. Group B: CAP patients
with only ARF on admission. Group C: CAP patients with both ARF and SS on admission.
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lobar infiltrate on CXR. Mortality rate in these patients
(Group C) was significantly different according to the
presence of monolobar vs. multilobar involvement on
CXR (37/179 patients, 21% vs. 48/116 patients, 41%, p <
0.001). No significant difference was observed among
patients with different levels of PaO2/FiO2 ratio in the
presence of monolobar involvement on CXR, whereas aTable 2 Risk factors associated to the presence of isolated ac
and severe sepsis on admission in the study population
Only acute respiratory
failure on admission
Age 1.02 (1.01-1.03) <0.001
Chronic obstructive pulmonary disease 2.08 (1.60-2.70) <0.001
Multilobar infiltrate 1.96 (1.51-2.55) <0.001
Pre-existing renal disease
Residency in nursing home
Female sex
Data represent odds ratio with 95% confidence intervals at multivariable binomial lsignificant difference was seen between different levels
of PaO2/FiO2 ratio in the presence of multilobar involve-
ment on CXR (p = 0.026).
Discussion
In the present study we showed different characteristics
on admission as well as significant differences in mortal-
ity among hospitalized patients with CAP according toute respiratory failure and both acute respiratory failure








Figure 1 In-hospital mortality of the study population according to the three study groups. Group A: Community-acquired pneumonia
(CAP) patients with neither acute respiratory failure (ARF) nor severe sepsis (SS) on admission. Group B: CAP patients with only ARF on admission.
Group C: CAP patients with both ARF and SS on admission. n: number.
Figure 2 The cumulative probability of survival in the three study groups. Group A: community-acquired pneumonia (CAP) patients with
neither acute respiratory failure (ARF) nor severe sepsis (SS) on admission. Group B: CAP patients with only ARF on admission. Group C: CAP
patients with both ARF and SS on admission. Adjusted for centers, sex, age, comorbidities (including congestive heart failure, cerebrovascular
accident, diabetes, chronic obstructive pulmonary disease, liver and renal diseases), residence in nursing home, multilobar infiltrate, pleural
effusion, empiric antibiotic therapy concordant with European respiratory Society guidelines.
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Figure 3 Multivariable logistic model with respect to in-hospital mortality. ARF: acute respiratory failure; SS: severe sepsis; COPD: chronic
obstructive pulmonary disease; ABT: antibiotic empiric therapy; ERS: European Respiratory Society; OR: odds ratio; CI: confident intervals. All the
variables are present vs. absent, but age (1-year change), male (vs. female) and multilobar (vs. monolobar).
Figure 4 In-hospital mortality in community-acquired pneumonia patients with only acute respiratory failure (ARF) on admission and
with both ARF and severe sepsis (SS) on admission stratified by mono- or multilobar involvement on chest X-ray and PaO2/FiO2 ratio
(P/F) levels on admission.
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groups of CAP patients have been identified: those with
neither ARF nor SS (4% mortality), those with only ARF
(9% mortality), and those with both ARF and SS on ad-
mission (26% mortality). After adjustment, ARF alone on
admission has an OR for mortality of 1.84 and the asso-
ciation of ARF and SS increases the OR for mortality up
to 6.55. Furthermore, the evaluation of the presence of
multilobar infiltrate on CXR on admission can help in
better stratifying CAP patients according to their risk of
death.
A lack of data exists about the prevalence of ARF in a
general population of CAP patients admitted to the hos-
pital. Furthermore, the characteristics of the patients en-
rolled in previous studies are very different from each
other, as well as definitions of ARF [3,13-15]. Although
all these factors make it difficult to compare the results,
the prevalence of ARF reported in previous literature
ranges between 16 to 73%, mostly in line with the 56%
of prevalence detected in our study. SS represents a
common complication in CAP patients, involving up to
34% of patients, and it seems to be acquired during the
first days of hospitalization [16,17]. The prevalence of SS
rises up to 67% in patients with ARF who are admitted to
the ICU for different diseases [18]. Our data are in line
with previous experiences showing the presence of SS on
admission in 20% of hospitalized patients with CAP.
We identified three different groups of patients with
CAP based on the absence of both ARF and SS, the pres-
ence of ARF alone, and the presence of both ARF and SS.
In view of the differences between patients belonging to
these three groups in terms of both baseline characteris-
tics and mortality, we could speculate that three distinct
clinical phenotypes of CAP patients exist. Furthermore,
we have shown that the evaluation of the presence of mul-
tilobar involvement on admission on CXR can help in
stratifying patients according to in-hospital mortality. A
recent meta-analysis by Mannu and coworkers showed
that multilobar involvement is an independent risk factor
for mortality [19]. We observed the highest in-hospital
mortality among CAP patients with ARF, severe sepsis
and multilobar infiltrates. Furthermore, we were able to
unmask an effect of gas exchange (PaO2/FiO2 ratio) on in-
hospital mortality only in this group of patients. Multilo-
bar involvement is a well-known reflection of the severity
of the CAP and could indicate either a direct involvement
of the microbial challenge or an indirect involvement in
the context of acute respiratory distress syndrome
(ARDS). Based on our results, it could be suggested that
in patients with both severe sepsis and ARF due to a mul-
tilobar CAP, the lung should be considered as the starting
point of a systemic inflammatory response such as for
ARDS and not just as an organ affected by a single infec-
tious process.The findings of the present study could lead to some
speculations from both a clinical and a research point of
view. Clinically, it is widely accepted that an early and cor-
rect identification of patients at risk of death is a crucial
step in the management of CAP patients and several indi-
ces to predict mortality have been developed [20]. Al-
though these scores have been validated in the scientific
literature over the last 20 years, it seems they have serious
difficulties to be implemented in daily clinical practice and
that they are inconsistent with clinical judgment in a sig-
nificant percentage of patients in low risk classes [21-23].
Furthermore, it has been recently shown that the CURB-
65, the most simple tool suggested by international guide-
lines to decide hospitalization for CAP patients, suffers of
a lack a formal assessment of hypoxemia, a major draw-
back in light of the importance of assessing oxygenation
immediately on arrival at the ER [24,25]. Furthermore, no
score in the decision to hospitalize patients in the ICU has
been widely accepted in clinical practice [26,27]. Some au-
thors have suggested a more pathophysiological and sim-
ple approach in the assessment of severity of CAP based
on evaluation of the presence of ARF and SS [28]. The
three-group classification of CAP patients we proposed
could be useful in this sense and may help to build up a
new algorithm for the site-of-care decision [29].
A meta-analysis of the data from our three study sites
showed no heterogeneity in the risks associated with
ARF and ARF/SS, validating that these are consistent,
robust phenotypes. The presence of these three groups
that clearly differ in characteristics and outcomes makes
it necessary to search for different underlying biological
and molecular processes. Previous data have shown a
different genotype association for septic shock and hyp-
oxemic ARF in CAP patients [30]. The identification of
these three clinically different phenotypes would be an
important guide in the interpretation of the large
amount of information that will possibly come from the
“-omics” world in next few years. The explanation at a
basic level of these clinical findings could finally allow
the development of new and interesting therapeutic
measurements, especially in CAP patients with SS.
Our study has some limitations. We were not able to
collect data concerning the response to fluid challenge
in case of initial hypotension. Thus, patients with septic
shock are included in the severe sepsis definition, al-
though a higher mortality should be expected in these
patients. Time to first antibiotic dose and treatment of
ARF and SS during hospitalization were not evaluated in
our study. However, recent data suggest that time to first
antibiotic dose should be interpreted as marker of opti-
mal care in CAP patients rather than a predictor of out-
comes [31]. Furthermore, all three centers have standard
operating procedure for CAP patients and ARF and SS
are managed according to international guidelines.
Aliberti et al. Respiratory Research 2014, 15:27 Page 9 of 10
http://respiratory-research.com/content/15/1/27Our study was strengthened by the evaluation of three
large cohorts of consecutive, prospectively enrolled pa-
tients in three different regions in Europe in very large
and robust data collections. The second main strength is
that we described a population, easy to identify with
clinical and laboratory variable collected at the emer-
gency room, having a high probability to die, which is a
target population to implement intensive treatment. This
concept fits perfectly with the idea of CAP as a medical
emergency [32].
Conclusions
The foremost conclusion of our study is that the identifi-
cation of ARF and SS on hospital admission can help
physicians in classifying CAP patients into three differ-
ent clinical phenotypes: those with neither ARF nor SS,
those with only ARF and those with both ARF and SS.
Since these three groups of patients show different char-
acteristics and outcomes, this simple and intuitive classi-
fication could be used in the site-of-care decision for
CAP patients with the goal to start as early as possible
the appropriate treatment in the right setting.
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